Medical Advocates

ARV/HAART
/cART
  Starting Therapy 
              

General Reports
When to Start
Number of Drugs
Dosing
First-Line Regimens
Drug Sequencing
Quality of Life
INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Trial.

 

HAART Main Page Main New/Newsworthy  Home Page

Last Update:  November 08, 2017
 
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

     Journal Papers, Abstracts, and Commentaries
 
 

FULL-TEXT ARTICLE
HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: An observational study.
Henrich TJ, Hatano H, Bacon O, et al
PLoS Med. 2017 Nov 7;14(11):e1002417
Paper

FULL-TEXT ARTICLE
Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: A randomized unblinded trial.
Koenig SP, Dorvil N, Dévieux JG,  et al 
PLoS Med. 2017 Jul 25;14(7):e1002357.
Paper

Immediate Initiation of Antiretroviral Therapy for HIV Infection Accelerates Bone Loss Relative to Deferring Therapy: Findings from the START Bone Mineral Density Substudy, a Randomized Trial.
Hoy JF, Grund B, Roediger M,
J Bone Miner Res. 2017 Jun 26.
Abstract

When is Early Antiretroviral Therapy Early Enough for HIV Remission?
Poveda E, Cresp M.
AIDS Rev
. 2017 May 23;19(2).
Abstract

Initiating antiretroviral therapy for HIV at a patient's first clinic visit: A cost-effectiveness analysis of the RapIT randomized controlled trial.
Long LC, Maskew M, Brennan AT,  et al
AIDS. 2017 May 1
Abstract

Intracellular HIV-1 rna and CD4+ t cell activation in patients starting antiretrovirals.
El-Diwany R, Breitwieser FP, Soliman M, et al
AIDS
. 2017 Mar 29.
Abstract

FULL-TEXT ARTICLE
Early Antiretroviral Therapy is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations
Oliveira MF, Chaillon A, Nakazawa M, et al
PLoS Pathog
. 2017 Jan 3;13
.
Paper

FULL-TEXT ARTICLE
Early Antiretroviral Therapy is Associated with Lower HIV DNA Molecular Diversity and Lower Inflammation in Cerebrospinal Fluid but Does Not Prevent the Establishment of Compartmentalized HIV DNA Populations
Oliveira MF, Chaillon A, Nakazawa M, et al 
PLoS Pathog
. 2017 Jan 3;13.
Paper

Systemic inflammation before and after antiretroviral therapy initiation as a predictor of immune response among HIV-infected individuals in Manitoba.
Richert Q, Trajtman A, Arroyave L, et al
Cytokine. 2016 Dec 21;91:74-81.
Abstract

A Multi-State Model Examining Patterns of Transitioning Among States of Engagement in Care in HIV-Positive Individuals Initiating Combination Antiretroviral Therapy.
Gillis J, Loutfy M, Bayoumi AM, et al
J
Acquir Immune Defic Syndr. 2016 Dec 15;73(5):531-539.
Abstract

The per-protocol effect of immediate vs. deferred ART initiation in the START randomized trial.
Lodi S, Sharma S, Lundgren JD,  et al  
AIDS
. 2016 Sep 6.
Abstract

Rapid HIV Viral Load Suppression in those Initiating Antiretroviral Therapy at First Visit after HIV Diagnosis.
Hoenigl M, Chaillon A, Moore DJ, et al 
Sci Rep. 2016 Sep 6;6:32947.
Abstract

Factors associated with the selection of initial antiretroviral therapy from 2009 to 2012.
Saag MS, Westfall AO, Cole SR, et al
J Acquir Immune Defic Syndr
.
2016 Aug 19
.
Abstract

The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a U.S. Public Health Setting.
Pilcher CD, Ospina-Norvell C, Dasgupta A,  et al
J Acquir Immune Defic Syndr. 2016 Jul 16..

Abstract

FULL-TEXT ARTICLE
Major influence of CD4 count at the initiation of cART on viral and immunological reservoir constitution in HIV-1 infected patients.
Depincé-Berger AE, Vergnon-Miszczycha D, Girard A,  et al
Retrovirology
. 2016 Jun 30;13(1):44.
Paper

Choice of initial regimen for antiretroviral-naïve HIV patients: Analysis of motivation.
Rouveix E, Mortier E, Beauchet A, et al
Rev Med Interne
. 2016 Jun 29.
Abstract

Initiation of Antiretroviral Therapy during Acute HIV-1 Infection leads to A High Rate of Non-Reactive HIV Serology.
de Souza MS, Pinyakorn S, Akapirat S,
Clin Infect Dis. 2016 Jun 17.
Abstract

Limiting Cumulative HIV Viremia Copy Years by Early Treatment Reduces Risk of AIDS and Death.
Olson AD, Walker AS, Suthar AB, et al
J Acquir Immune Defic Syndr
. 2016 Apr 21.
Abstract

FULL-TEXT ARTICLE
Impact of Early Initiation of Antiretroviral Therapy in Patients with Acute HIV Infection in Vienna, Austria.
Herout S, Mandorfer M, Breitenecker F,
PLoS One. 2016 Apr 11;11(4):e0152910.
Paper

Antiretroviral therapy initiation and adherence in rural South Africa: community health workers' perspectives on barriers and facilitators.
Loeliger KB, Niccolai LM, Mtungwa LN,
AIDS Care
. 2016 Apr 4:1-12
Abstract

FULL-TEXT ARTICLE
Early HAART Initiation May Not Reduce Actual Reproduction Number and Prevalence of MSM Infection: Perspectives from Coupled within- and between-Host Modelling Studies of Chinese MSM Populations.
Sun X, Xiao Y, Tang S, et al
PLoS One
. 2016 Mar 1;11(3):e0150513.
Paper

FULL-TEXT ARTICLE
A Randomized Trial of Time-Limited Antiretroviral Therapy in Acute/Early HIV Infection.
Margolick JB, Apuzzo L, Singer J, et al
PLoS One
. 2015 Nov 24;10(11):e0143259
Paper

Psychosocial factors associated with late HAART initiation in Mexican patients with HIV.
Nogueda-Orozco MJ, Caro-Vega Y, Crabtree-Ramírez B,
Salud Publica Mex. 2015;57 Suppl 2:s135-s141.
Abstract

Late initiation of combination antiretroviral therapy in Canada: a call for a national public health strategy to improve engagement in HIV care.
Cescon A, Patterson S, Davey C,  et al

J Int AIDS Soc
. 2015 Oct 5;18(1):20024
Abstract

Superior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapy.
Kerschberger B, Boulle AM, Kranzer K,  et al

J Int AIDS Soc
. 2015 Sep 23;18(1):20092.

Abstract

Early initiation rather than prolonged duration of antiretroviral therapy in HIV infection contributes to the normalization of CD8+ T-cell counts.
Cao W, Mehraj V, Trottier B, et al

Clin Infect Dis
. 2015 Sep 8.
Abstract

FULL-TEXT ARTICLE
Reasons and Risk Factors for the Initial Regimen Modification in Chinese Treatment-Naïve Patients with HIV Infection: A Retrospective Cohort Analysis.
Sun J, Liu L, Shen J, et al
P
LoS One
. 2015 Jul 24;10(7):e0133242
Paper

Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.
Lima VD, Reuter A, Harrigan PR,et al
AIDS. 2015 Jul 9
Abstract

FULL-TEXT ARTICLE
Does transient cART started during primary HIV infection undermine the long-term immunologic and virologic response on cART resumption?
Krastinova E, Seng R, Lechenadec J,  et al
BMC Infect Dis. 2015 Apr 10;15(1):178.
Paper

Beginning Antiretroviral Therapy for Patients with HIV.
Johnson JA, Sax PE.

I
nfect Dis Clin North Am
. 2014 Sep;28(3):421-438..
Abstract

Antiretroviral therapy initiation in an Australian cohort: implications for increased use of antiretroviral therapy.
Stratov I, Kent SJ.
Eur J Clin Microbiol Infect Dis. 2014 Aug 20.
Abstract

FULL-TEXT ARTICLE
Efficacy of Initial Antiretroviral Therapy for HIV-1 Infection in Adults: A Systematic Review and Meta-Analysis of 114 Studies with up to 144 Weeks' Follow-Up
Lee FJ, Amin J, Carr A.
PLoS One
. 2014 May 15;9(5):e9748.
Paper

Factors Informing HIV Providers' Decisions to Start Antiretroviral Therapy for Young People Living With Behaviorally Acquired HIV.
Lee L, Rand CS, Ellen JM, Agwu AL.  et al ,
J Adolesc Health
. 2014 Apr 29
Abstract

Recent trends in early stage response to combination antiretroviral therapy in Australia.
McManus H, Hoy JF, Woolley I, et al
Antivir Ther. 2014 Apr 4.
Abstract

Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial.
Grinsztejn B, Hosseinipour MC, Ribaudo HJ,  et al
 
Lancet Infect Dis. 2014 Mar .3
Abstract

Trends of CD4 cell count levels at the initiation of antiretroviral therapy over time and factors associated with late initiation of antiretroviral therapy among Asian HIV-positive patients.
Kiertiburanakul S, Boettiger D, Lee MP, et al

J Int AIDS So
c
. 2014 Mar 14;17(1):18804.
Abstract

FULL-TEXT ARTICLE
Timing of Antiretroviral Therapy Initiation after a First AIDS-Defining Event: Temporal Changes in Clinical Attitudes in the ICONA Cohort.
Cingolani A, Cozzi-Lepri A, Ammassari A,  et al

PLoS One
. 2014 Feb 27;9(2):e89861.
Paper

Durability of the First Antiretroviral Treatment Regimen and Reasons for Change in Patients With HIV Infection.
De La Torre-Lima J, Aguilar A,  et al

HIV Clin Trials
. 2014 Jan-Feb;15(1):27-35.
Abstract

Antiretroviral therapy for initial human immunodeficiency virus/AIDS treatment: critical appraisal of the evidence from over 100 randomized trials and 400 systematic reviews and meta-analyses.
Kanters S, Mills EJ, Thorlund K,  et al

Clin Microbiol Infec
t
. 2014 Feb;20(2):114-22.
Abstract

Starting treatment according to guidelines evaluation: a multicentre audit of HIV patients in the UK.
Reeves I, Premchand N, Schwenk A,  et al
Int J STD AIDS
. 2013 Mar;24(3):243-4.
Abstract

Predictors of virologic response in persons who start antiretroviral therapy during recent HIV infection.
Karris MY, Kao YT, Patel D, et al
AIDS. 2014 Jan 3.

Abstract

Can early therapy reduce inflammation?
Sandler NG, Sereti I.
Curr Opin HIV AIDS. 2013 Nov 15
.
Abstract

Community views: balancing the public health benefits of earlier antiretroviral treatment with the implications for individual patients - perspectives from the community.
Collins S, Geffen N.
Curr Opin HIV AIDS
. 2013 Nov 15.
Abstract

FULL-TEXT ARTICLE
Role of HIV Infection Duration and CD4 Cell Level at Initiation of Combination Anti-Retroviral Therapy on Risk of Failure.

Lodi S, Phillips A, Fidler S,  et al
PLoS One
. 2013 Sep 24;8(9):e75608
Paper

The Detection and Management of Early HIV Infection: A Clinical and Public Health Emergency.
Smith MK, Rutstein SE, Powers KA, et al
J Acquir Immune Defic Synd
r
. 2013 Jul;63 Suppl 2:S187-99
.
Abstract

Australian prescribers' perspectives on ART initiation in the era of "treatment as prevention"
Mao L, de Wit J, Adam P,et al
AIDS Care
. 2013 Feb 13
Abstract

Impact of geneticfactorsondyslipidemia in HIV-infected patients starting antiretroviral therapy.
Egaña-Gorroño L, Martínez E,  et al 
AIDS. 2012 Dec 19..
Abstract

Timing of cART initiation after a first AIDS-defining event (ADE): temporal changes in clinical attitudes in a large cohort of HIV-infected patients.
Cingolani A, Cozzi-Lepri A, Ammassari A, et al
J
Int AIDS Soc
. 2012 Nov 11;15(6):18200..
Abstract

Balancing Immunological Benefits and Cardiovascular Risks of Antiretroviral Therapy: When Is Immediate Treatment Optimal?
Negoescu DM, Owens DK, Brandeau ML, Bendavid
E.
Clin Infect Dis. 2012 Aug 31.
Abstract

Choice of Initial Combination Antiretroviral Therapy in Individuals With HIV Infection: Determinants and Outcomes.
Elzi L, Erb S, Furrer H, Ledergerber B, et al

Arch Intern Med
. 2012 Aug 13:.
Abstract

Effects of Antiretroviral Therapy on Autonomic Function in Early HIV Infection: A Preliminary Report.
Chow D, Kocher M, Shikuma C
Int J Med Sci. 2012;9(5):397-405.
7-405.
Abstract

FULL-TEXT ARTICLE
No Treatment versus 24 or 60 Weeks of Antiretroviral Treatment during Primary HIV Infection: The Randomized Primo-SHM Trial.
Grijsen ML, Steingrover R, Wit FW, et al

PLoS Med
. 2012 Mar;9(3):e1001196.

Paper

Should We Treat Acute HIV Infection?
O'Brien M, Markowitz M.
Curr HIV/AIDS Rep. 2012 Mar 14. .

Abstract

Impact of Time to Start Treatment Following Infection with Application to Initiating HAART in HIV-Positive Patients.
Lok JJ, Degruttola V.

Biometrics. 2012 Feb 21..
Abstract

Changing predictors of mortality over time from cART start: implications for care.
Hoffmann CJ, Katherine FL, Victoria J, et al

J Acquir Immune Defic Syndr
. 2011 Aug 26.
Abstract

Triple class experience after initiation of combination antiretroviral treatment in Australia: survival and projections.
Pour SM, Woolley I, Canavan P, et al

Sex Health
. 2011 Sep;8(3):295-303.
Abstract

Response to HAART in Treatment-Naive HIV-Infected Patients with a Prior Diagnosis of Tuberculosis or other Opportunistic Infections.
Dronda F, Sobrino P, Hernández-Novoa B, et al
Curr HIV Res. 2011 Jun 2...
Abstract

Management of HIV infection in treatment-naive patients: A review of the most current recommendations.
Boyd SD.|
Am J Health Syst Pharm
. 2011 Jun 1;68(11):991-1001..
Abstract

A decision tree to help determine the best timing and antiretroviral strategy in HIV-infected patients.
Piroth L, Fournel I, Mahy S,  et al

Epidemiol Infect
. 2011 Jan 14:1-10..
Abstract

FULL-TEXT ARTICLE
Criticality of Timing for Anti-HIV Therapy Initiation.
Castiglione F, Paci P.

PLoS One
. 2010 Dec 23;5(12):e15294.
Paper

Younger age at HAART initiation is associated with more rapid growth reconstitution.
McGrath CJ, Chung MH, Richardson BA,  et al

AIDS
. 2010 Nov 22
Abstract

 

     Conference Reports, Abstracts, and Posters
 
 
Early treatment during HIV-1 acute infection attenuates GI damage, inflammation and immune activation but does not prevent CD4+ T cell depletion in the lamina propia
C. Deleage, A. Schuetz, D. Morcock, et al
(XX International AIDS Conference)
Abstract

When to Start Therapy
 

     Book
  Implications for a policy of initiating antiretroviral therapy in people diagnosed with human immunodeficiency virus: the CAPRA research programme.
Miltz A, Phillips AN, Speakman A, et al
Southampton (UK): NIHR Journals Library; 2017 Oct

 

     Journal Papers, Abstracts, and Commentaries

 
What Level of Risk Compensation Would Offset the Preventive Effect of Early Antiretroviral Therapy? Simulations From the TEMPRANO Trial.[Côte d'Ivoire,]
Jean K, Boily MC, Danel C, et al
Am J Epidemiol. 2016 Oct 24.
Abstract
 

The Benefits of Early Antiretroviral Therapy for HIV Infection: How Early is Early Enough?
Lee SA, Deeks SG.  
EBioMedicine
. 2016 Aug 5.
.
Abstract

Is early antiretroviral therapy initiation useful in HIV(+) adults without co-infections?
Chauriye V, Monsalve X.
Medwave. 2015 Dec 2;15(Suppl 3):e6326
Abstract

Update on antiretroviral treatment during primary HIV infection.
Ambrosioni J, Nicolas D, Sued O,  et al
Expert Rev Anti Infect Ther
. 2014 May 7
Abstract

A Comparative Systematic Review of the Optimal CD4 Cell Count Threshold for HIV Treatment Initiation.
Olubajo B, Mitchell-Fearon K, Ogunmoroti O.
Interdiscip Perspect Infect Dis. 2014;2014:625670
Abstract

Antiretroviral Therapy Initiated within Six Months of HIV Infection is Associated with Lower T-cell Activation and Smaller HIV Reservoir Size.
Jain V, Hartogensis W, Bacchetti P,  et al;
J Infect Dis
. 2013 Jul 12.
Abstract

FULL-TEXT ARTICLE
Evaluating the Effect of Early Versus Late ARV Regimen Change if Failure on an Initial Regimen: Results From the AIDS Clinical Trials Group Study A5095.
Li L, Eron JJ, Ribaudo H, Gulick RM, Johnson BA.

J Am Stat Assoc
. 2012;107(498):542-55
4.
Paper

Clinician Practices and Attitudes Regarding Early Antiretroviral Therapy in the US.
Kurth AE, Mayer K, Beauchamp G,  et al
J Acquir Immune Defic Syndr
. 2012 Jul 23

Abstract

When to Start ART in the Setting of Acute AIDS-Related Opportunistic Infections: The Time Is Now!
Grant PM, Zolopa AR.

Curr HIV/AIDS Rep
. 2012 Jun 26.
 
Abstract

FULL-TEXT ARTICLE
Survival Outcomes and Effect of Early vs. Deferred cART Among HIV-Infected Patients Diagnosed at the Time of an AIDS-Defining Event: A Cohort Analysis.
Miro JM, Manzardo C, Mussini C,  et al

PLoS One
. 2011;6(10):e26009.
Paper

Timing of HAART initiation and clinical outcomes in human immunodeficiency virus type 1 seroconverters.
Writing Committee for the CASCADE Collaboration
Arch Intern Med
. 2011 Sep 26;171(17):1560-9..
Abstract

When to start antiretroviral therapy.
Rhame FS.
Curr Infect Dis Rep. 2011 Feb;13(1):60-7
Abstract

FULL-TEXT ARTICLE
Criticality of Timing for Anti-HIV Therapy Initiation.
Castiglione F, Paci P.
PLoS One
. 2010 Dec 23;5(12):e15294.
Paper

Impact of earlier HAART initiation on the immune status and clinical course of treated patients on the basis of cohort data of the German Competence Network for HIV/AIDS.
Plettenberg A, Brockmeyer NH, Haastert B,
et al
Infection
. 2011 Jan 11.
Abstract

Estimating the Optimal CD4 Count for HIV-infected Persons to Start Antiretroviral Therapy.
Shepherd BE, Jenkins CA, Rebeiro PF, et al

Epidemiology
. 2010 Jun 25.
Abstract

Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children.
HIV Paediatric Prognostic Markers Collaborative Study.
AIDS
. 2010 Apr 9
Abstract

Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults.
Siegfried N, Uthman OA, Rutherford GW.

Cochrane Database Syst Rev
. 2010 Mar 17;3
Abstract

When and why to start antiretroviral therapy?
Gatell JM.

J Antimicrob Chemother
. 2010 Jan 12
Abstract

 

Early Therapy
 

     Journal Papers, Abstracts, and Commentaries

  The Effects of Early Antiretroviral Therapy and Its Discontinuation on the HIV-Specific Antibody Response.
Killian MS, Norris PJ, Rawal BD, et al
 
AIDS Res Hum Retroviruses.
2006 Jul;22(7):640-7

Abstract

Number of Drugs
     

Quadruple Drug Therapy

     Journal Papers, Abstracts, and Commentaries
 

  Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Hoen B, Cooper DA, Lampe FC, et al

Clin Infect Dis.
2007 Aug 1;45(3):381-90.
Abstract
 
Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Gulick RM, Ribaudo HJ, Shikuma CM, et al
JAMA.
2006 Aug 16;296(7):769-81.
Abstract
 
 

 

Triple Drug Therapy
 
     Journal Papers, Abstracts, and Commentaries
 
  A Randomized Open-Label Study of Three- versus Five-Drug Combination Antiretroviral Therapy in Newly HIV-1 Infected Individuals.
Markowitz M, Evering TH, Garmon D, Caskey M,  et al

J Acquir Immune Defic Syndr
. 2014 Jan 21.
Abstract

Multiple Drugs

     Journal Papers, Abstracts, and Commentaries

  A Randomized Open-Label Study of Three- versus Five-Drug Combination Antiretroviral Therapy in Newly HIV-1 Infected Individuals.
Markowitz M, Evering TH, Garmon D, Caskey M,  et al
J Acquir Immune Defic Syndr
. 2014 Jan 21.
Abstract

Rates of Disease Progression among Human Immunodeficiency Virus-Infected Persons Initiating Multiple-Drug Rescue Therapy.
Lee N, Hogg RS, Yip B, et al
J Infect Dis
. 2003 Jul 1;188(1):137-41.
Abstract
 
FULL-TEXT ARTICLE
Systematic review and meta-analysis of evidence for increasing numbers of drugs in
antiretroviral combination therapy
Jordan R,  Gold L, Cummins C, Hyde C
B
MJ 2002;324:757
Paper
 
3-4 Drugs vs 2 Drugs

     Journal Papers, Abstracts, and Commentaries

  Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection.
Rutherford GW, Feldman KA, Kennedy GE
Cochrane Database Syst Rev 2000;(2):CD002037
Abstract

Dosing
 

     Journal Papers, Abstracts, and Commentaries 

  Daily dosing of highly active antiretroviral therapy.
Rosenbach KA, Allison R, Nadler JP.
Clin Infect Dis 2002 Mar 1;34(5):686-92
Abstract

Drug Sequencing
 

     Journal Papers, Abstracts, and Commentaries
 
 
Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility.
Zoete V, Michielin O, Karplus M.
J Mol Biol 2002 Jan 4;315(1):21-52
Abstract
 
A rational approach to the selection and sequencing of nucleoside/nucleotide analogues: a new paradigm.
Lange J.
Antivir Ther 2001;6 Suppl 3:45-54
Abstract

FULL-TEXT PDF ARTICLE
Health-related quality of life in individuals infected with HIV in the era of HAART.
Miners AH, Sabin CA, Mocroft A, et al.
HIV Clin Trials 2001 Nov-Dec;2(6):484-92
Paper

INSIGHT Strategic Timing of AntiRetroviral Treatment (START) Trial.
 

     Journal Papers, Abstracts, and Commentaries
 
 
Prevalence of and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment
START) trial.
Carr A, Grund B, Neuhaus J,  et al

HIV Med
. 2015 Apr;16 Suppl 1:137-46.
Abstract

Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Matthews G, Neuhaus J, Bhagani S,  et al 
HIV Med. 2015 Apr;16 Suppl 1:129-36.
Abstract

Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts > 500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Kunisaki K, Niewoehner, Collins G, et al
 
HIV Med
. 2015 Apr;16 Suppl S1:119-128.
Abstract

Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Baker J, Engen N, Huppler Hullsiek K, et al

HIV Med
. 2015 Apr;16 Suppl 1:109-18

Abstract

Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Wright E, Grund B, Cysique, et al

HIV
Med
. 2015 Apr;16 Suppl S1:97-108.
Abstract

Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Lifson A, Grandits G, Gardner E, et al

HIV Med
. 2015 Apr;16 Suppl 1:88-96.
Abstract

Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Baxter J, Dunn D, White E, et al

HIV Med
. 2015 Apr;16 Suppl 1:77-87.
Abstract

Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Rodger A, Lampe F, Grulich A,  et al
HIV Med. 2015 Apr;16 Suppl S1:64-76.
Abstract

Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Achhra A, Mocroft A, Ross M, et al

HIV Med
. 2015 Apr;16 Suppl 1:55-63.
Abstract

Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Soliman E, Sharma S, Arastéh K,  et al

HIV Med
. 2015 Apr;16 Suppl S1:46-54.
Abstract

Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Law M, Achhra A, Deeks S,  et al

HIV Med
. 2015 Apr;16 Suppl 1:37-45
Abstract

Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Sharma S, Babiker A, Emery S, et al
HIV Med. 2015 Apr;16 Suppl 1:30-6.
Abstract

Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Denning E, Sharma S, Smolskis M,  et al
HIV Med. 2015 Apr;16 Suppl 1:24-9.
Abstract

Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Grarup J, Rappoport C, Engen N,  et al

HIV Med
. 2015 Apr;16 Suppl 1:14-23
Abstract

Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial.
Geffen N, Aagaard P, Corbelli G,  et al

HIV Med
. 2015 Apr;16 Suppl 1:10-3.

Abstract

 


HAART Main Page Main New/Newsworthy  Home Page

 Starting Therapy in ARV-Naive Patients